Phd Degree / Doktora
Permanent URI for this collectionhttps://hdl.handle.net/11147/2869
Browse
3 results
Search Results
Doctoral Thesis Therapeutic Efficacy Of Intrathecal Administration Of AAVrh10-mHEXA Vector In A Mouse Model Of Tay-Sachs Disease(01. Izmir Institute of Technology, 2025) Can Özgür, Melike; Seyrantepe, VolkanTay-Sachs hastalığı, bir lizozomal depolama hastalığıdır ve HEXA genindeki mutasyonlar sonucu oluşmaktadrr. HEXA geni, GM2 gangliosidini parçalamaktan sorumlu β-hekzosaminidaz A enziminin α-alt birimini kodlar. Son zamanlarda, Hexa ve Neu3 genlerinin birleşik eksikliklerine sahip Tay-Sachs hastalığı fare modeli (DKO fareleri), şiddetli nöropatolojik semptomlar ve nöroinflamasyon sergileyerek 20 haftaya kadar hayatta kalmıştır. Birçok lizozomal depolama hastalığı için tedavi stratejileri değerlendirilmiş olsa da, Tay-Sachs hastalığı için etkin tedaviler henüz geliştirilememiştir. Bu çalışmada, AAVrh10-mHexa (AAV) vektörünün intratekal uygulanmasının DKO farelerinde terapötik etkinliğini araştırmayı amaçladık. Ayrıca, AAV ilişkili gen tedavisi ile bir anti-inflamatuar ajanı olan istradefylline tedavisinin, DKO farelerinde nöroinflamasyonu hafifletme potansiyelini değerlendirdik. Moleküler biyolojik, immünohistokimyasal ve davranışsal analizler yapıldı. AAV tek başına ve istradefylline ile kombinasyon halinde uygulandıktan sonra DKO farelerinin yaşam süresinin 30 haftaya kadar uzadığını gösterdik. Moleküler biyolojik analizler, AAV tedavisi uygulanan ve istradefylline ile kombinasyon halinde tedavi edilen DKO farelerinin korteks, beyincik ve böbrek, karaciğer ve dalak gibi organlarında Hexa aktivitesinin arttığını ve lizozomal markerlar ile pro-inflamatuar sitokinler olan Ccl2 ve Ccl3 seviyelerinin azaldığını ortaya koydu. İmmünohistokimyasal veriler, AAV ve AAV-istradefylline kombinasyonu ile tedavi edilen farelerin beyinlerinde GM2 birikintisinin temizlendiğini, lizozom sayılarının azaldığını, aktif astrosit düzeylerinin düştüğünü ve nöronlar ile oligodendrositlerde iyileşmeler olduğunu gösterdi. Ayrıca, bu farelerde motor aktivitesi de iyileşti. Bu sonuçlar, AAVrh10 ilişkili intratekal uygulamanın, tek başına veya istradefylline ile kombinasyon halinde, Tay-Sachs hastalığını tedavi etmek için umut verici bir terapötik yaklaşım olduğunu göstermektedir.Doctoral Thesis Investigation of the Effects of Antiinflammatory in the Tissues of Gm2 Gangliosidosis Mouse Model(01. Izmir Institute of Technology, 2023) Ateş, Nurselin; Seyrantepe, VolkanTay- Sachs disease is an autosomal recessively inherited lysosomal storage disorder caused by mutations on the HEXA gene encoding α-subunit of β- Hexosaminidase A enzyme. The enzyme catalyzes GM2 to GM3 conversion but when it is deficient the GM2 degradation is interrupted and GM2 ganglioside is progressively accumulated especially in neurons. Progressive accumulation of GM2 causes increasing death of neurons, disruption in mental and motor functions and eventually death at 2-4 years of age. The Hexa-/- Tay-Sachs model was normal thanks to a bypass mechanism mediated by Neurominidase3. It was determined that Hexa-/-Neu3-/- mice mimicked the neuropathologic and clinical phenotype of the Tay-Sachs disease. Previously we showed GM2 accumulation in Hexa-/-Neu3-/- Tay Sachs disease mouse model triggers release of proinflammatory cytokines, microgliosis, astrogliosis consequently activation of inflammatory cascades as well as oxidative stress. These inflammatory events contribute to neurodegeneration observed in the disease pathology. In Sandhoff Disease mouse model it was shown that astrocytes express adenosine A2A receptors which induces ccl2 chemokine overexpression. A2A receptor antagonist istradefylline treatment reduces microglial activation and ccl2 expression in Sandhoff mice. In this study; A2A receptor antagonist istradefylline treatment was applied to Tay Sachs disease mouse model and whether this treatment would alleviate the neuroinflammation and redox imbalance; and prolong the lifespan was investigated by molecular biological and behavioural analyses. Modulation of ccl2 expression by istradefylline was used as potential therapeutic target to slow down Tay Sachs disease mouse model.Doctoral Thesis Understanding the Biological Role of Sialidase Neu3 in Tay-Sachs Disease Mouse Model(Izmir Institute of Technology, 2019) Akyıldız Demir, Seçil; Seyrantepe, VolkanTay-Sachs disease is a severe lysosomal storage disorder characterized by mutations in the lysosomal ß-Hexosaminidase A (HEXA) enzyme which converts GM2 to GM3 ganglioside. The GM2 ganglioside accumulation is observed predominantly in the neurons. The infants appear normal in their inborn time, but the progressive accumulation of undegraded GM2 results with death. Hexa-/- mice were created. However, they have a normal lifespan with no obvious neurological impairment until one year. It was thought that stored GM2 catabolized to GA2 using sialidase(s), which is further processed by HEXB. To determine the contribution of sialidase NEU3 to degradation of GM2, a mouse with combined deficiencies of Hexa and Neu3 genes was generated. The Hexa-/-Neu3-/- mice were healthy at birth, but they died between 1.5 and 5 months of age. Thin-layer chromatography and mass spectrometric analysis of the brains of Hexa-/-Neu3-/- mice revealed the abnormal accumulation of GM2. The progressive GM2 accumulation was also verified on testes, liver, and kidney of Hexa-/- Neu3-/- mice. GM2 accumulation in the brain leads to increased lysosomes with membranous cytoplasmic bodies, Purkinje cell depletion, cytoplasmic vacuolization, astrogliosis, and age-dependent lessening in neurons and oligodendrocytes. These mice have prominent disorders such as growth impairment, skeletal bones abnormalities, slow movement, tremors, anxiety and age-dependent loss in both memory and muscle strength. Consequently, the Hexa-/-Neu3-/- mice mimic the pathological, biochemical and clinical abnormalities of the Tay-Sachs patients, and useful model for the future understanding of cellular pathologies that drive the progression of the disease. They are a suitable model for the future pre-clinical testing of possible treatments.